anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
PURPOSE:To obtain a skin beautifying agent having actions to suppress melanogenesis and dissipate pigmentation formed by the stimulation with ultraviolet rays, etc., and giving a skin cosmetic having excellent skin beautifying effect and the preventing and treating effect on the spots and freckles caused by sunburn, etc. CONSTITUTION:A skin beautifying agent composed of a compound of the formula (R<1> and R<2> are OH, lower alkoxy or sulfate residue) and a skin cosmetic containing the compound. The compound of the formula can be separated from the extraction liquid of the twig of southern bayberry (Myrica cerifera). The amount of compound of the formula to be compounded to the skin cosmetic is preferably 0.00001-10wt.%, especially 0.0001-5wt.%. This skin cosmetic includes quasi-drugs and medicines for external use, etc., as well as common skin cosmetics. It is used in various forms such as cream, milky lotion, face lotion, foundation, pack, lotion, gel, solution or stick according to the use.
PURPOSE:To obtain a stationary phase where a holding body and finding protein make stable crosslinking bond by using the holding body and immuno globulin contg. epitope of a measuring object bonding to the surface of the holding body via the bond group formed by glycol cleavage of saccharide. CONSTITUTION:The stationary phase is obtd. from the bonding body and the immuno globulin contg. epitope of the measuring object bonding to the surface of the holding body via the bond group formed by glycol cleavage of saccharide. The glycoprotein such as receptor in the stationary phase is oxidized by the glycol cleavage, by which the aldehyde for crosslinking bonding to the stationary phase, usually dialdehyde is formed. The immuno globulin is particularly impor tant as the receptor, for which the immuno globulines from arbitrary vertebrate groups such as mouse, rabbit and human are used. A wide range of solid holding bodies such as silica or adjusted glass beads are usable as a packing material. The particles used for chromatography are typically porous and the pressure necessary for executing the chromatography varies with particle sizes. The higher pressure is needed for the smaller particles.
PURPOSE:To provide a non-reducing glucide-producing enzyme having excellent stability to produce a non-reducing glucide having trehalose structure from a partial decomposition product of redpcing starch, having good sweet taste, absorbable and digestible by oral ingestion and giving a glucide useful as a sweetener, taste-improving agent, etc. CONSTITUTION:The objective new enzyme is produced by culturing a microbial strain [e.g. Rhizobium sp. M-11 (FERM BP-4130)] capable of producing a non- reducing glucide-producing enzyme having trehalose structure from a partial decomposition product of reducing starch. The enzyme has an action to form a non-reducing glucide having trehalose structure on the terminal from a partial decomposition product of one or more kinds of reducing starches having a glucose polymerization degree of >=3. It has a molecular weight of about 76,000-87,000 Dalton measured by SDS-get electrophoresis, an isoelectric point pI of about 3.6-4.6 measured by an ampholinecontaining electrophoresis, optimum temperature of 35-40 deg.C and optimum pH of 6.4-7.2 and is stable at a temperature up to about 35-40 deg.C at pH 7.0 for 60min and stable at pH 5.5-11.0 at 25 deg.C for 16hr.
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Non-adherence to antiepileptic drugs (AEDs) is a common problem (i.e., 58% of patients have some level of non-adherence) for youth with epilepsy, with potentially devastating consequences. Adolescents with epilepsy represent a particularly vulnerable group, given their increased independence, decreased parental supervision, higher risk for deficits in organization and memory, busy and changing schedules, low motivation, and increased susceptibility to peer influence. Existing adherence interventions in epilepsy are not designed to meet the unique challenges faced by adolescents, and there are no efficacious interventions for adolescents with epilepsy. Not surprisingly, without efficacious interventions, adherence worsens during adolescence, further increasing the risk of poor health outcomes during this developmental period. While reminder strategies (e.g., automated digital reminders) are effective for the most common adherence barriers of forgetting and busy schedules, they are likely to be ineffective in increasing motivation. Leveraging social norms comparison methods (i.e., feedback about someone else's behavior related to one's own behavior) offers an opportunity to capitalize on the increased importance of peer influence while simultaneously targeting the low motivation characteristic of adolescents. Recent data in adolescents indicates that social norms interventions have incremental value and improve health behaviors above and beyond standard feedback without peer comparisons. Consistent with the ORBIT model for behavioral intervention development, our aims are to: 1) develop a feasible, accessible, and acceptable mHealth social norms intervention for improving AED adherence in adolescents with epilepsy and 2) obtain preliminary efficacy data and effect sizes for a future clinical trial. We conducted a pilot RCT of an mHealth social norms intervention (ORBIT Phase II). Adolescents with epilepsy who demonstrate non-adherence (\< 95% adherence based on PI's previous RCTs; 58% of sample) during baseline will be randomized to either 1) mHealth social norms (automated digital reminders, individualized adherence feedback, and social norms feedback) or 2) control (automated digital reminders and individualized adherence feedback). Both groups will receive active intervention for five months. Primary (i.e., electronically-monitored adherence) and secondary outcomes (i.e., seizure severity, HRQOL) will be assessed post-treatment and 3 months later, respectively. If successful, the results of this study would have a large impact on pediatric epilepsy, with the potential to change clinical practice for treating non-adherence by reducing common barriers to behavioral health care. Because minimal clinician time is required, our mHealth social norms intervention also has potential for sustainability and broad dissemination for epilepsy and other pediatric conditions
Methods: Patients with resectable pancreatic cancer will be treated with oxaliplatin 85 mg/m² IV over 2 hours, irinotecan 150 mg/m² given concurrently with folinic acid 400 mg/m² IV over 90 min, followed by a 46-hour infusion of 5-fluorouracil 2400 mg/m². Slow oral digitalization will be used starting with a daily dose of 0.125 (patients over age 65) or 0.25 mg (patients 65 or younger) PO daily. A steady-state will be achieved after five half-lives, which is about 7 to 10 days in the average subject. The initial blood level will be obtained one week after starting digoxin. Assuming the digoxin level is at steady-state and the renal function is stable, there is a linear relationship between digoxin dose and serum concentration. The target digoxin level is between 0.8 to 1.2 ng/mL. Patients will receive IV chemotherapy at 2 week intervals. Restaging imaging will be performed after 4 doses. If the patient has stable or responsive disease, an additional 4 doses will be given followed by restaging imaging. The patient will then undergo surgical exploration \~ 4 weeks after the last dose of chemotherapy.

Clinical Endpoints: Primary Endpoints: clinical toxicity. Other endpoints: status of pathologic margins, response rate, pathologic stage, progression-free survival, and overall survival.

Correlative Endpoints: Baseline exome sequencing of circulating cell free tumor DNA. Measurement of quantity of circulating cell free tumor DNA at 4 week intervals while on chemotherapy and prior to surgery; resume at 3 month intervals after surgery. Genomic DNA will be collected at baseline for pharmacogenetic studies of polymorphisms that may be pertinent for the drugs used in the study. Blood will be collected for analysis of possible biomarkers of response to digoxin modulation.
BACKGROUND: Cervical cancer is the second leading cause of cancer death among Ethiopian women. This study aimed to assess the influence of the health system on access to cervical cancer prevention, screening, and treatment services at public health centers in Addis Ababa, Ethiopia.
METHODS: This study used a cross-sectional survey design and collected data from 51 randomly selected public health centers in Addis Ababa. Open Data Kit was used to administer a semi-structured questionnaire on Android tablets, and SPSS version 26 was used to analyze the descriptive data.
RESULTS: In the study conducted at 51 health centers, cervical cancer prevention and control services achieved 61% HPV vaccination for girls, 79% for cervical cancer awareness messages, 80% for precancer lesion treatment, and 71% for cervical screening of women. All health centers were performing cervical screening mostly through visual inspection with acetic acid due to the inconsistent availability of HPV DNA tests and the lack of Pap smear tests. In 94% of health centers, adequate human resources were available. However, only 78% of nurses, 75% of midwives, 35% of health officers, and 49% of health extension workers received cervical cancer training in the 24 months preceding the study. Women had provider choices in only 65% of health centers, and 86% of the centers lacked electronic health records. In 41% of the health centers, the waiting time was 30 minutes or longer. About 88% and 90% of the facilities lacked audio and video cervical cancer messages, respectively.
CONCLUSION: This study revealed that the annual cervical cancer screening achievement was on track to fulfill the WHO's 90-70-90 targets by 2030. We recommend that decision-makers prioritize increasing HPV vaccination rates, enhancing messaging, reducing wait times, and implementing electronic health records to improve access to cervical cancer services in Addis Ababa.
Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
GD1 is a prototypical lysosomal storage disorder and the first disorder to have compelling evidence of successful treatment with enzyme replacement therapy. The common clinical manifestations are hematologic cytopenias, hepatomegaly, splenomegaly, and a spectrum of skeletal pathologies. Disease expression is diverse. The rate and extent of disease progression are variable and often independent of the age at which symptoms are first reported1. Despite a long history of treatment efficacy2, there is significant heterogeneity of response among patients with regard to the maximum improvement in hematologic, visceral, bone, and other manifestations and the dynamic speed of response during therapy1-3. There have been few well-designed studies that comprehensively annotate phenotypic variation over time or measure treatment efficacy and dose response. In part, this is attributable to lack of a validated disease severity scoring system for GD1 to standardize the monitoring of progression and treatment response and to define patient cohorts in clinical studies.

DS3 is a method of expressing an integrated assessment of the burden of disease in a given patient. It can be used to monitor patient status, determine endpoints in clinical studies, classify disease phenotypes and compare patients with the same disease. Although frequently referred to as 'disease severity indices,' DS3 instruments may also include measures of disease activity and damage. DS3s utilize a minimal data set to score the patient in a comprehensive manner. They usually are structured as a group of domains (often according to organ system) that are populated with non-redundant items that are valid, reliable, use feasible, standardized methods of assessment, and that are variably weighted based on associated morbidity and mortality. A DS3 for adult GD1 patients was recently developed and subjected to successful preliminary testing for validity, reliability and feasibility4. With respect to changes over time, a minimal clinically important difference was defined. Construct validity has been partially demonstrated. Using 20 patient profiles from the International Collaborative Gaucher Group (ICGG) Gaucher Registry, the instrument was shown to correlate very well with the "gold standard" clinical global impression scale. However, larger scale testing in a population that is representative of the world wide distribution of GD1 phenotypes (including splenectomy patients) is needed and predictive validity has yet to be determined. Moreover, the DS3 has not yet been correlated with disease-specific measures of response such as achievement of therapeutic goals or broadly used biomarkers. Combining retrospective and prospective analysis, this study is designed to address these issues
Study Design Subjects: Ten patients will be enrolled in this pilot study. Eligibility criteria: (i) age 30-70 years old, (ii) diagnosis of refractory unipolar major depression, (iii) recurrent illness with a minimum four major depressive episodes, (iv) current episode duration of no less than twelve months; (v) current episode treatment failure to a minimum of four treatment classes-including serotonin-reuptake inhibitors (SSRI), other novel agents, monoamine oxidase inhibitors (MAOI), tricyclics; somatic treatments such as ECT or vagus nerve stimulation (VNS); some form of psychotherapy. Exclusion criteria (i) previous brain surgery (ii) neurological disorder of any type, (iii) significant psychiatric comorbidity as defined by DSM IV diagnostic criteria (such as schizophrenia, panic disorder) (iv) serious medical conditions or contraindication for surgery such as cardiac pacemaker/defibrillator or other implanted devices. Full medical records from a treating psychiatrist will first be reviewed by Dr. Kennedy. Eligible patients will then undergo a full psychiatric, neurological and neuropsychological evaluation (Appendix 1 and 2). Final selection will be made by consensus of the investigative team in collaboration with a senior independent psychiatrist Robert Cooke, MD with expertise in intractable mood disorders. Informed consent will be obtained prior to entering the study.
Family members receive health coaching sessions over 50-60 minutes monthly for 6 months. Family members also receive navigation sessions with a LHW monthly for 6 months and church-based peer support monthly for 6 months.
Sulforaphane has been isolated and identified as a major and very potent phase II enzyme inducer in broccoli (Brassica oleracea italica). Sulforaphane is a monofunctional inducer, inducing phase II enzymes selectively without the induction of aryl hydrocarbon receptor-dependent cytochromes P-450 (phase I enzymes). Analogues differing in the oxidation state of sulfur and the number of methylene groups were synthesized, and their inducer potencies were measured. Sulforaphane is the most potent of these analogues. Other analogues having different substituent groups in place of the methylsulfinyl group of sulforaphane were also synthesized and assessed. Of these, the most potent are 6-isothiocyanato-2-hexanone and exo-2-acetyl-6-isothiocyanatonorbornane.
OBJECTIVES: Endoscopic retrograde cholangiopancreatography (ERCP) represents the gold standard for jaundice palliation in patients with distal malignant biliary obstruction (DMBO). Biliary drainage using electrocautery lumen apposing metal stent (EC-LAMS) is currently a well-established procedure when ERCP fails. In a palliative setting the endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) could represent an easy and valid option. We performed a prospective study with a new EC-LAMS with the primary aim to assess the clinical success rate of EUS-GBD as a first-line approach to the palliation of DMBO.
METHODS: In all, 37 consecutive patients undergoing EUS-GBD with a new EC-LAMS were prospectively enrolled. Clinical success was defined as bilirubin level decrease >15% within 24 h and >50% within 14 days after EC-LAMS placement.
RESULTS: The mean age was 73.5 ± 10.8 years; there were 17 male patients (45.9%). EC-LAMS placement was technically feasible in all patients (100%) and the clinical success rate was 100%. Four patients (10.8%) experienced adverse events, one bleeding, one food impaction, and two cystic duct obstructions because of disease progression. No stent-related deaths were observed. The mean hospitalization was 7.7 ± 3.4 days. Median overall survival was 4 months (95% confidence interval 1-8).
CONCLUSION: Endoscopic ultrasound-guided gallbladder drainage with the new EC-LAMS is a valid option in palliative endoscopic biliary drainage as a first-step approach in low survival patients with malignant jaundice unfit for surgery. A smaller diameter EC-LAMS should be preferred, particularly if the drainage is performed through the stomach, to avoid potential food impaction, which could result in stent dysfunction.
FIELD: ophthalmology.SUBSTANCE: group of inventions relates to ophthalmology, namely to an ophthalmic composition and a method for providing or facilitating the penetration or absorption of a drug through the corneal membrane. An ophthalmic composition for topical use contains a poorly water-soluble drug and a carrier that contains oil, one or more surfactants and one or more cosolvents; moreover, the specified composition is capable of self-emulsification when mixed with an aqueous solution when instilled into an eye. The composition contains from 5% to 60% wt. /wt. of oil. The composition contains less than 1% wt. of water. Oil is selected from the group consisting of one long chain triglyceride, one medium chain triglyceride, a medium chain monoglyceride and a medium chain diglyceride, a surfactant selected from the group consisting of purified polyoxyl-35-castor oil, polyoxyl-40-hydrogenated castor oil and polysorbate 80, and the co-solvents are selected from the group consisting of polyethylene glycol 300, polyethylene glycol 400, and propylene glycol.EFFECT: group of inventions helps to obtain a thermodynamically stable microemulsion that does not degrade over time. The group of inventions also improves the residence time in an eye.41 cl, 8 ex, 16 tbl, 13 dwg
Proteinic material comprising the purified human or animal gamma globulin is suspended under the aseptic conditions in such amount of distilled apyrogenic water with the temperature from 0 to 6 °C, so that the concentration of proteins was in the scope 5 to 180 g/l. From the solution the lipoproteins are precipitated by adding the polyethyleneglycol with molecular weight 4,000 to 10,000, whilst the produced preparation is mixed or matured for at least two hours and maximally for 24 hours under the temperature 0 to 6 °C. Lipoproteins precipitate is separated from the gamma globulins solution by centrifugation and the solution is clarified by filtration or by other suitable physical method. Consequently the separation of ballast compounds up to molecular weight 150,000 is realised in the surrounding of apyrogenic distilled water or in the aqueous solution of NaCl in distilled apyrogenic water in concentration up to 30 g/l under the temperature 0 to 6 °C with pH 4.0 to 8.0. Such obtained form of monomer IgG is concentrated, sterilised and before chamber lyophilisation the solution is stabilised by adding the NaCl, glucose, maltose or other sugars. The solution is filled, its freezing and lyophilisation is performed, in the case of necessity the solution of gamma globulin is submitted before or after lyophilisation to the other processing through the ion changing or affinity chromatography to obtain qualitative parameters IgG.
Age-related macular degeneration (AMD) can lead to irreversible impairment of visual function, and the number of patients with AMD has been increasing globally. The immunoinflammatory theory is an important pathogenic mechanism of AMD, with macrophages serving as the primary inflammatory infiltrating cells in AMD lesions. Its powerful immunoinflammatory regulatory function has attracted considerable attention. Herein, we provide an overview of the involvement of macrophage-regulated immunoinflammation in different stages of AMD. Additionally, we summarize novel therapeutic approaches for AMD, focusing on targeting macrophages, such as macrophage/microglia modulators, reduction of macrophage aggregation in the subretinal space, modulation of macrophage effector function, macrophage phenotypic alterations, and novel biomimetic nanocomposites development based on macrophage-associated functional properties. We aimed to provide a basis and reference for the further exploration of AMD pathogenesis, developmental influences, and new therapeutic approaches.
The invention relates to the technical field of biomedicine and biomedicine, in particular to a method for establishing an experimental model of burn and chronic kidney disease. The method comprises the steps of performing adenine infusion on the burn-associated chronic kidney disease experimental model to induce chronic kidney disease, establishing a stable burn-associated chronic kidney disease experimental model by matching with the burn to accelerate the development of the chronic kidney disease after the chronic kidney disease is successfully induced, and performing performance identification on the prepared burn-associated chronic kidney disease mouse model. The invention discloses an animal research model for burn complicated with chronic kidney disease and application thereof. Chronic kidney disease was first induced with adenine and then the backs of the mice were subjected to burn treatment. After burn, the kidney function of the mice is obviously reduced, and the kidney injury is obviously aggravated. This model can be used to study the effect of burns on renal function, particularly long-term effects. The invention has great scientific significance and social benefit for medical research of the burned kidney injury and also has good application prospect.